Nanofiber compositions for a vaccine adjuvant, porous scaffold or porous membrane

Patent metadata

Field	Value
Publication number	US-2020360513-A1
Application number	US-202016877185-A
Country	US
Kind code	A1
Filing date	May 18, 2020
Priority date	May 17, 2019
Publication date	Nov 19, 2020
Grant date	—

Abstract

An aspect is directed to a vaccine adjuvant including a nanofiber that comprises an oxide or a salt of one, two, three or more metals selected from the group of Al, Ca, Mg, Li, Na, K, La, Y, Si, Fe and Zn. Another aspect is directed to a porous scaffold or a porous membrane that comprises nanofibers comprising an oxide or a salt of one, two, three or more metals selected from the group of Al, Ca, Mg, Li, Na, K, La, Y, Si, Fe and Zn, where the porous scaffold or the porous membrane is configured for use in an environment where the nanofibers are exposed to a direct contact with extracellular body fluids.

First claim

1 . A vaccine adjuvant, comprising:
a nanofiber with a diameter in the range from around 1 nm to around 500 nm, a length in the range from around 250 nm to around 500 μm, an aspect ratio in the range from around 10 to around 100,000, a total internal open pore volume in the range from around 0.01 cm 3 /g to around 3 cm 3 /g, and an average pore size in the range from around 0.5 nm to around 50 nm, wherein the nanofiber comprises an oxide or a salt of one, two, three or more metals selected from the group of Al, Ca, Mg, Li, Na, K, La, Y, Si, Fe and Zn.

2 . The vaccine adjuvant of claim 1 , wherein the nanofiber aspect ratio ranges from around 100 to around 10,000, the nanofiber length ranges from around 1.5 μm to around 150 μm, the nanofiber average pore size ranges from around 0.5 nm to around 20 nm, and the nanofiber pore volume is in the range from around 0.05 cm 3 /g to around 1 cm 3 /g.

3 . The vaccine adjuvant of claim 1 , wherein the nanofiber exhibits a positive surface charge in the range from around +2.00 mV to around +80.00 mV, as measured using Zeta-potential at a pH between about 7-8.

4 . The vaccine adjuvant of claim 1 ,
wherein the nanofiber is one of a plurality of nanofibers with diameters in the range from around 1 nm to around 500 nm, lengths in the range from around 250 nm to around 500 μm, and aspect ratios in the range from around 10 to around 100,000, and wherein a total weight fraction of the plurality of nanofibers relative to all other inorganic metal oxides or inorganic metal salts in the adjuvant composition ranges from around 10 wt. % to around 100 wt. %.

5 . The vaccine adjuvant of claim 1 , further comprising:
(i) a solution or suspension of mineral salts, (ii) one, two, three or more tensoactive compounds, (iii) one, two, three or more microorganism-derived adjuvants, (iv) one or more emulsions, (v) one, two, three or more surfactants, (vi) one, two, three or more different cytokines, (vii) one, two, three or more of polysaccharides, (viii) one, two, three or more nucleic acid-based adjuvants, (ix) one, two, three or more of immunostimulants, or (x) any combination thereof.

6 . The vaccine adjuvant of claim 1 , wherein Al constitutes between around 50 at. % to around 100 at. % of all the metals in the metal oxide or the metal salt of the nanofiber.

7 . The vaccine adjuvant of claim 1 , wherein Ca constitutes between around 50 at. % to around 100 at. % of all the metals in the metal oxide or the metal salt of the nanofiber.

8 . The vaccine adjuvant of claim 1 , wherein Mg constitutes between around 50 at. % to around 100 at. % of all the metals in the metal oxide or the metal salt of the nanofiber.

9 . The vaccine adjuvant of claim 1 , wherein Zn constitutes between around 50 at. % to around 100 at. % of all the metals in the metal oxide or the metal salt of the nanofiber.

10 . The vaccine adjuvant of claim 1 , wherein the metal oxide or the metal salt comprises two or more metals with an atomic fraction of more than 0.01 at. % relative to all other metals in the metal oxide or the metal salt.

11 . The vaccine adjuvant of claim 1 , wherein the metal oxide or the metal salt of the nanofiber comprises one, two or more of the following:
(i) metal oxide, (ii) metal hydroxide, (iii) metal oxyhydroxide, (iv) metal sulfate, (v) metal carbide, (vi) metal phosphate, (vii) metal hydroxy phosphate, (viii) metal hydroxy phosphate sulfate, (ix) metal phosphate sulfate, (x) metal carbonate, (xi) metal carbonate phosphate, and (xii) metal hydroxy sulfate.

12 . The vaccine adjuvant of claim 1 , wherein the nanofiber is a transformation of a metal-organic nanofiber.

13 . The vaccine adjuvant of claim 12 , wherein the metal-organic nanofiber is an alkoxide.

14 . The vaccine adjuvant of claim 13 , wherein the alkoxide is a methoxide, an ethoxide, an iso-propoxide, or n-propoxide.

15 . The vaccine adjuvant of claim 14 , wherein the metal-organic nanofiber is produced upon exposure of particles or chunks or bulk pieces of metals or Li-containing metal alloys to at least one alcohol.

16 . The vaccine adjuvant of claim 1 , wherein the vaccine adjuvant is configured to provide an active acquired immunity to an infectious disease, selected from at least one of the following: malaria, adenovirus, anthrax, cholera, diphteria, hepatitis A, hepatitis B, acquired immunodeficiency syndrome (AIDS), Haemiphilius influenza type b, human papilloma virus (HPV), seasonal influenza (Flu), Japanese Encephalitis, measles, meningococcal, mumps, pertussis, pneumococcal, polio, rabies, rotavirus, rubella, shingles, smallpox, tetanus, tuberculosis, varicella, yellow fewer, one or more coronavirus-induced diseases, or a combination thereof.

17 . A porous scaffold or a porous membrane, comprising:
nanofibers with an average diameter in the range from around 1 nm to around 500 nm, an average length in the range from around 250 nm to around 500 μm, an average aspect ratio in the range from around 10 to around 100,000, an average total internal open pore volume in the range from around 0.01 cm 3 /g to around 3 cm 3 /g, and an average pore size in the range from around 0.5 nm to around 50 nm, wherein the nanofibers comprise an oxide or a salt of one, two, three or more metals selected from the group of Al, Ca, Mg, Li, Na, K, La, Y, Si, Fe and Zn, and wherein the porous scaffold or the porous membrane is configured for use in an environment where the nanofibers are exposed to a direct contact with extracellular body fluids.

18 . The porous scaffold or porous membrane of claim 17 , wherein the porous scaffold or the porous membrane is configured to facilitate wound healing.

19 . The porous scaffold or porous membrane of claim 18 , wherein the nanofibers comprise one or more antiseptic agents to combat bacteria or virus growth.

Assignees

• Sila Nanotechnologies Inc

Inventors

• Yushin Gleb
• Turcheniuk Kostiantyn
• Kulinski Kyle

Classifications

• A61L2400/12

  Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61K2039/55511

  Organic adjuvants · CPC title

• A61K39/39 Primary

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title

• A61K2039/55555

  Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers · CPC title